LARIMAR THERAPEUTICS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
LARIMAR THERAPEUTICS, INC. (LRMR) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $184.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-03-19
- LARIMAR THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $34.00M, a 41.38% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $36.50M, a 27.00% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-12-31 was $58.00M.
- LARIMAR THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2024-09-30 was $50.00M.
- LARIMAR THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $184.00M, a 28.67% increase from fiscal 2024.
- LARIMAR THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $143.00M.
- LARIMAR THERAPEUTICS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2015 was $195.99M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-12-31 | $34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $70.50M derived: sum of 2 quarters · filed 2026-03-19 | $184.00M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $36.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $150.00M 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $113.50M 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | $58.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $108.00M derived: sum of 2 quarters · filed 2026-03-19 | $143.00M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $50.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $85.00M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $35.00M 10-Q · filed 2025-08-14 | |||
| 2016-09-30 | $52.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $92.23M derived: sum of 2 quarters · filed 2016-11-09 | $141.37M 10-Q · filed 2016-11-09 | $197.94M derived: sum of 4 quarters · filed 2016-11-09 |
| 2016-06-30 | $39.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $88.66M 10-Q · filed 2016-08-05 | $145.23M derived: sum of 3 quarters · filed 2016-08-05 | $204.93M derived: sum of 4 quarters · filed 2016-11-09 |
| 2016-03-31 | $49.13M 10-Q · filed 2016-05-10 | $105.70M derived: sum of 2 quarters · filed 2016-05-10 | $165.41M derived: sum of 3 quarters · filed 2016-11-09 | $215.87M derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-12-31 | $56.57M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $116.27M derived: sum of 2 quarters · filed 2016-11-09 | $166.74M derived: sum of 3 quarters · filed 2016-11-09 | $195.99M 10-K · filed 2016-03-15 |
| 2015-09-30 | $59.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $110.17M derived: sum of 2 quarters · filed 2016-11-09 | $139.42M 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $50.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $79.72M 10-Q · filed 2016-08-05 | ||
| 2015-03-31 | $29.25M 10-Q · filed 2016-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |